BAJAJ BROKING
Wockhardt Ltd’s Miqnaf (nafithromycin), approved by CDSCO for CABP, is an ultra-short course antibiotic targeting drug-resistant pathogens. Despite the news, Wockhardt share price declined by 0.88%.
Pharmaceutical company Wockhardt Ltd has received approval from the Central Drugs Standard Control Organization (CDSCO) for Miqnaf (nafithromycin), a novel treatment for Community-Acquired Bacterial Pneumonia (CABP) in adults. The antibiotic offers an ultra-short course regimen of once-a-day dosage for three days, targeting multi-drug resistant (MDR) pathogens.
Also read: Biocon Gets China NMPA Approval for Tacrolimus Capsules
Innovative Regimen: Ultra-short, three-day course for improved patient compliance.
Target Pathogens: Effective against MDR bacteria like S. pneumoniae and H. influenzae.
Clinical Trials: Tested in the US, Europe, South Africa, and India.
India’s Disease Burden: India accounts for 23% of global CABP cases.
Also read: Avenue Supermarts Reports 17.5% Revenue Growth in Q3 FY25
Miqnaf is the first macrolide-based antibiotic introduced in India in nearly 30 years, addressing a critical gap in CABP treatment. It is designed to combat antibiotic-resistant strains, reducing the need for hospitalisation in severe cases. This aligns with efforts to mitigate India’s growing antibiotic resistance crisis, which significantly impacts the treatment of respiratory infections.
Feature | Details |
Treatment Duration | 3 days, once daily |
Target Pathogens | MDR strains, including S. pneumoniae |
Clinical Studies | Conducted across US, Europe, and India |
Disease Focus | CABP and other respiratory infections |
Wockhardt plans to launch Miqnaf in the Indian market within a few months. With India bearing a significant global disease burden for CABP, Miqnaf is expected to play a pivotal role in improving treatment outcomes.
The approval of Miqnaf signifies a significant advancement in CABP treatment, addressing antibiotic resistance and improving compliance. Despite this milestone, Wockhardt share price declined by 0.88%, closing at ₹1,445.75.
Also read: IRFC Partners REMCL to Fund Renewable Energy for Railways
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading